Stockreport

Trillium Therapeutics' TTI-621 an Orphan Drug in U.S. for T-cell lymphoma; shares ahead [Seeking Alpha]

Trillium Therapeutics Inc. - Common Shares  (TRIL) 
Last trillium therapeutics inc. - common shares earnings: 5/13 07:00 am Check Earnings Report
PDF Trillium Therapeutics' TTI-621 an Orphan Drug in U.S. for T-cell lymphoma; shares aheadTrillium Therapeutics (NASDAQ:TRIL) is up6% premarket on light volume in response [Read more]